Picture of Haemonetics logo

HAE — Haemonetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Haemonetics Corp expected to post earnings of 89 cents a share - Earnings Preview

* Haemonetics Corp  HAE.N   HAE  is expected to show a rise
in
quarterly revenue when it reports  results on May 9 for the
period ending March 31 2024
    * The Boston Massachusetts-based  company is expected to
report a
8.1% increase in revenue to $329.113 million from $304.42
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Haemonetics Corp is for
earnings of 89 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Haemonetics
Corp
is $105.00​, above​ its last closing price of $95.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.95        0.94       1.04      Beat    10.5
 Sep. 30 2023  0.88        0.89       0.99      Beat    11.5
 Jun. 30 2023  0.72        0.73       1.05      Beat    43.7​
 Mar. 31 2023  0.72        0.70       0.77      Beat    9.2
 ​​Dec.        0.83        0.80       0.85      Beat    5.9
 31 2022                                                
 Sep. 30 2022  0.68        0.67       0.83      Beat    23.2​
 Jun. 30 2022  0.51        0.51       0.58      Beat    13.6
 Mar. 31 2022  0.60        0.60       0.65      Beat    8.2
 This summary was machine generated May 7 at 10:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Haemonetics

See all news